PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors Article Swipe
Roxanne Charlebois
,
Bertrand Allard
,
David Allard
,
Laurence Buisseret
,
Martin Turcotte
,
Sandra Pommey
,
Pavel Chrobák
,
John Stagg
·
YOU?
·
· 2016
· Open Access
·
· DOI: https://doi.org/10.1158/0008-5472.can-16-1873
YOU?
·
· 2016
· Open Access
·
· DOI: https://doi.org/10.1158/0008-5472.can-16-1873
Innate and adaptive immune cells play an important role in the therapeutic activity of anti-ErbB2 mAbs, such as trastuzumab. In the clinic, breast tumors poorly infiltrated with immune cells are more resistant to trastuzumab, and patients have a worse prognosis. Because type I and II IFNs are critical to the immune-mediated activity of anti-ErbB2 mAb, we investigated the effect of combining polyI:C and CpG with trastuzumab-like therapy in immunocompetent mouse models of ErbB2+ breast cancer. We demonstrated that in situ delivery of polyI:C and CpG combined to systemic anti-ErbB2 mAb triggered a potent inflammatory response in breast tumors able to induce long-lasting CD8+ T cell–dependent antitumor immunity. Remarkably, polyI:C and CpG was superior to combined PD-1/CTLA-4 blockade in sensitizing tumors to anti-ErbB2 mAb therapy. Local injection of CpG and polyI:C in a primary tumor significantly enhanced the activity of systemic anti-ErbB2 mAb against a distant untreated tumor. Type I and II IFNs, as well as natural killer cells and CD8+ T cells, were indispensible to the synergistic activity of the combination treatment. Because synthetic RNA analogues and CpG oligodeoxynucleotides have been safely used in clinical trials, our study supports combination treatments with anti-ErbB2 mAbs. Cancer Res; 77(2); 312–9. ©2016 AACR.
Related Topics
Concepts
Trastuzumab
Immune system
Cancer research
Monoclonal antibody
Immunotherapy
Breast cancer
Medicine
Immunology
CD8
Cancer
CpG site
Acquired immune system
Innate immune system
Immune checkpoint
Antibody
Biology
Internal medicine
Gene
Gene expression
Biochemistry
DNA methylation
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1158/0008-5472.can-16-1873
- https://cancerres.aacrjournals.org/content/canres/77/2/312.full.pdf
- OA Status
- bronze
- Cited By
- 31
- References
- 29
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2549800333
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2549800333Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/0008-5472.can-16-1873Digital Object Identifier
- Title
-
PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint InhibitorsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2016Year of publication
- Publication date
-
2016-11-21Full publication date if available
- Authors
-
Roxanne Charlebois, Bertrand Allard, David Allard, Laurence Buisseret, Martin Turcotte, Sandra Pommey, Pavel Chrobák, John StaggList of authors in order
- Landing page
-
https://doi.org/10.1158/0008-5472.can-16-1873Publisher landing page
- PDF URL
-
https://cancerres.aacrjournals.org/content/canres/77/2/312.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://cancerres.aacrjournals.org/content/canres/77/2/312.full.pdfDirect OA link when available
- Concepts
-
Trastuzumab, Immune system, Cancer research, Monoclonal antibody, Immunotherapy, Breast cancer, Medicine, Immunology, CD8, Cancer, CpG site, Acquired immune system, Innate immune system, Immune checkpoint, Antibody, Biology, Internal medicine, Gene, Gene expression, Biochemistry, DNA methylationTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
31Total citation count in OpenAlex
- Citations by year (recent)
-
2024: 1, 2022: 6, 2021: 2, 2020: 8, 2019: 2Per-year citation counts (last 5 years)
- References (count)
-
29Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2549800333 |
|---|---|
| doi | https://doi.org/10.1158/0008-5472.can-16-1873 |
| ids.doi | https://doi.org/10.1158/0008-5472.can-16-1873 |
| ids.mag | 2549800333 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/27872096 |
| ids.openalex | https://openalex.org/W2549800333 |
| fwci | 2.32523669 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000818 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Animals |
| mesh[1].qualifier_ui | Q000494 |
| mesh[1].descriptor_ui | D000911 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | pharmacology |
| mesh[1].descriptor_name | Antibodies, Monoclonal |
| mesh[2].qualifier_ui | Q000276 |
| mesh[2].descriptor_ui | D000970 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | immunology |
| mesh[2].descriptor_name | Antineoplastic Agents |
| mesh[3].qualifier_ui | Q000494 |
| mesh[3].descriptor_ui | D000970 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | pharmacology |
| mesh[3].descriptor_name | Antineoplastic Agents |
| mesh[4].qualifier_ui | Q000037 |
| mesh[4].descriptor_ui | D060908 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | antagonists & inhibitors |
| mesh[4].descriptor_name | CTLA-4 Antigen |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D005260 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Female |
| mesh[6].qualifier_ui | Q000276 |
| mesh[6].descriptor_ui | D007369 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | immunology |
| mesh[6].descriptor_name | Interferon Inducers |
| mesh[7].qualifier_ui | Q000494 |
| mesh[7].descriptor_ui | D007369 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | pharmacology |
| mesh[7].descriptor_name | Interferon Inducers |
| mesh[8].qualifier_ui | Q000187 |
| mesh[8].descriptor_ui | D016246 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | drug effects |
| mesh[8].descriptor_name | Lymphocytes, Tumor-Infiltrating |
| mesh[9].qualifier_ui | Q000276 |
| mesh[9].descriptor_ui | D015674 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | immunology |
| mesh[9].descriptor_name | Mammary Neoplasms, Animal |
| mesh[10].qualifier_ui | Q000473 |
| mesh[10].descriptor_ui | D015674 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | pathology |
| mesh[10].descriptor_name | Mammary Neoplasms, Animal |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D051379 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Mice |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D008807 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Mice, Inbred BALB C |
| mesh[13].qualifier_ui | Q000276 |
| mesh[13].descriptor_ui | D009838 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | immunology |
| mesh[13].descriptor_name | Oligodeoxyribonucleotides |
| mesh[14].qualifier_ui | Q000494 |
| mesh[14].descriptor_ui | D009838 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | pharmacology |
| mesh[14].descriptor_name | Oligodeoxyribonucleotides |
| mesh[15].qualifier_ui | Q000276 |
| mesh[15].descriptor_ui | D011070 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | immunology |
| mesh[15].descriptor_name | Poly I-C |
| mesh[16].qualifier_ui | Q000494 |
| mesh[16].descriptor_ui | D011070 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | pharmacology |
| mesh[16].descriptor_name | Poly I-C |
| mesh[17].qualifier_ui | Q000037 |
| mesh[17].descriptor_ui | D061026 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | antagonists & inhibitors |
| mesh[17].descriptor_name | Programmed Cell Death 1 Receptor |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D060888 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Real-Time Polymerase Chain Reaction |
| mesh[19].qualifier_ui | Q000037 |
| mesh[19].descriptor_ui | D018719 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | antagonists & inhibitors |
| mesh[19].descriptor_name | Receptor, ErbB-2 |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D000818 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Animals |
| mesh[21].qualifier_ui | Q000494 |
| mesh[21].descriptor_ui | D000911 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | pharmacology |
| mesh[21].descriptor_name | Antibodies, Monoclonal |
| mesh[22].qualifier_ui | Q000276 |
| mesh[22].descriptor_ui | D000970 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | immunology |
| mesh[22].descriptor_name | Antineoplastic Agents |
| mesh[23].qualifier_ui | Q000494 |
| mesh[23].descriptor_ui | D000970 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | pharmacology |
| mesh[23].descriptor_name | Antineoplastic Agents |
| mesh[24].qualifier_ui | Q000037 |
| mesh[24].descriptor_ui | D060908 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | antagonists & inhibitors |
| mesh[24].descriptor_name | CTLA-4 Antigen |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D005260 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Female |
| mesh[26].qualifier_ui | Q000276 |
| mesh[26].descriptor_ui | D007369 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | immunology |
| mesh[26].descriptor_name | Interferon Inducers |
| mesh[27].qualifier_ui | Q000494 |
| mesh[27].descriptor_ui | D007369 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | pharmacology |
| mesh[27].descriptor_name | Interferon Inducers |
| mesh[28].qualifier_ui | Q000187 |
| mesh[28].descriptor_ui | D016246 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | drug effects |
| mesh[28].descriptor_name | Lymphocytes, Tumor-Infiltrating |
| mesh[29].qualifier_ui | Q000276 |
| mesh[29].descriptor_ui | D015674 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | immunology |
| mesh[29].descriptor_name | Mammary Neoplasms, Animal |
| mesh[30].qualifier_ui | Q000473 |
| mesh[30].descriptor_ui | D015674 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | pathology |
| mesh[30].descriptor_name | Mammary Neoplasms, Animal |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D051379 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Mice |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D008807 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Mice, Inbred BALB C |
| mesh[33].qualifier_ui | Q000276 |
| mesh[33].descriptor_ui | D009838 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | immunology |
| mesh[33].descriptor_name | Oligodeoxyribonucleotides |
| mesh[34].qualifier_ui | Q000494 |
| mesh[34].descriptor_ui | D009838 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | pharmacology |
| mesh[34].descriptor_name | Oligodeoxyribonucleotides |
| mesh[35].qualifier_ui | Q000276 |
| mesh[35].descriptor_ui | D011070 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | immunology |
| mesh[35].descriptor_name | Poly I-C |
| mesh[36].qualifier_ui | Q000494 |
| mesh[36].descriptor_ui | D011070 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | pharmacology |
| mesh[36].descriptor_name | Poly I-C |
| mesh[37].qualifier_ui | Q000037 |
| mesh[37].descriptor_ui | D061026 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | antagonists & inhibitors |
| mesh[37].descriptor_name | Programmed Cell Death 1 Receptor |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D060888 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | Real-Time Polymerase Chain Reaction |
| mesh[39].qualifier_ui | Q000037 |
| mesh[39].descriptor_ui | D018719 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | antagonists & inhibitors |
| mesh[39].descriptor_name | Receptor, ErbB-2 |
| type | article |
| title | PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors |
| biblio.issue | 2 |
| biblio.volume | 77 |
| biblio.last_page | 319 |
| biblio.first_page | 312 |
| topics[0].id | https://openalex.org/T10158 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Immunotherapy and Biomarkers |
| topics[1].id | https://openalex.org/T10580 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.9998000264167786 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2403 |
| topics[1].subfield.display_name | Immunology |
| topics[1].display_name | Immunotherapy and Immune Responses |
| topics[2].id | https://openalex.org/T11020 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.9990000128746033 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2403 |
| topics[2].subfield.display_name | Immunology |
| topics[2].display_name | Immune Cell Function and Interaction |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2779786085 |
| concepts[0].level | 4 |
| concepts[0].score | 0.7808041572570801 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q412616 |
| concepts[0].display_name | Trastuzumab |
| concepts[1].id | https://openalex.org/C8891405 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6767736673355103 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[1].display_name | Immune system |
| concepts[2].id | https://openalex.org/C502942594 |
| concepts[2].level | 1 |
| concepts[2].score | 0.639604389667511 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[2].display_name | Cancer research |
| concepts[3].id | https://openalex.org/C542903549 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5952281355857849 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q422248 |
| concepts[3].display_name | Monoclonal antibody |
| concepts[4].id | https://openalex.org/C2777701055 |
| concepts[4].level | 3 |
| concepts[4].score | 0.568946123123169 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[4].display_name | Immunotherapy |
| concepts[5].id | https://openalex.org/C530470458 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5407474040985107 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q128581 |
| concepts[5].display_name | Breast cancer |
| concepts[6].id | https://openalex.org/C71924100 |
| concepts[6].level | 0 |
| concepts[6].score | 0.5258634090423584 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[6].display_name | Medicine |
| concepts[7].id | https://openalex.org/C203014093 |
| concepts[7].level | 1 |
| concepts[7].score | 0.5093683004379272 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[7].display_name | Immunology |
| concepts[8].id | https://openalex.org/C167672396 |
| concepts[8].level | 3 |
| concepts[8].score | 0.49615010619163513 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q417800 |
| concepts[8].display_name | CD8 |
| concepts[9].id | https://openalex.org/C121608353 |
| concepts[9].level | 2 |
| concepts[9].score | 0.49069130420684814 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[9].display_name | Cancer |
| concepts[10].id | https://openalex.org/C140173407 |
| concepts[10].level | 5 |
| concepts[10].score | 0.48008233308792114 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q1138358 |
| concepts[10].display_name | CpG site |
| concepts[11].id | https://openalex.org/C193419808 |
| concepts[11].level | 3 |
| concepts[11].score | 0.4313780963420868 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q1645075 |
| concepts[11].display_name | Acquired immune system |
| concepts[12].id | https://openalex.org/C136449434 |
| concepts[12].level | 3 |
| concepts[12].score | 0.42461562156677246 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q428253 |
| concepts[12].display_name | Innate immune system |
| concepts[13].id | https://openalex.org/C2780851360 |
| concepts[13].level | 4 |
| concepts[13].score | 0.4163641333580017 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q21686041 |
| concepts[13].display_name | Immune checkpoint |
| concepts[14].id | https://openalex.org/C159654299 |
| concepts[14].level | 2 |
| concepts[14].score | 0.3871949017047882 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[14].display_name | Antibody |
| concepts[15].id | https://openalex.org/C86803240 |
| concepts[15].level | 0 |
| concepts[15].score | 0.28587204217910767 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[15].display_name | Biology |
| concepts[16].id | https://openalex.org/C126322002 |
| concepts[16].level | 1 |
| concepts[16].score | 0.128734290599823 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[16].display_name | Internal medicine |
| concepts[17].id | https://openalex.org/C104317684 |
| concepts[17].level | 2 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[17].display_name | Gene |
| concepts[18].id | https://openalex.org/C150194340 |
| concepts[18].level | 3 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q26972 |
| concepts[18].display_name | Gene expression |
| concepts[19].id | https://openalex.org/C55493867 |
| concepts[19].level | 1 |
| concepts[19].score | 0.0 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[19].display_name | Biochemistry |
| concepts[20].id | https://openalex.org/C190727270 |
| concepts[20].level | 4 |
| concepts[20].score | 0.0 |
| concepts[20].wikidata | https://www.wikidata.org/wiki/Q874745 |
| concepts[20].display_name | DNA methylation |
| keywords[0].id | https://openalex.org/keywords/trastuzumab |
| keywords[0].score | 0.7808041572570801 |
| keywords[0].display_name | Trastuzumab |
| keywords[1].id | https://openalex.org/keywords/immune-system |
| keywords[1].score | 0.6767736673355103 |
| keywords[1].display_name | Immune system |
| keywords[2].id | https://openalex.org/keywords/cancer-research |
| keywords[2].score | 0.639604389667511 |
| keywords[2].display_name | Cancer research |
| keywords[3].id | https://openalex.org/keywords/monoclonal-antibody |
| keywords[3].score | 0.5952281355857849 |
| keywords[3].display_name | Monoclonal antibody |
| keywords[4].id | https://openalex.org/keywords/immunotherapy |
| keywords[4].score | 0.568946123123169 |
| keywords[4].display_name | Immunotherapy |
| keywords[5].id | https://openalex.org/keywords/breast-cancer |
| keywords[5].score | 0.5407474040985107 |
| keywords[5].display_name | Breast cancer |
| keywords[6].id | https://openalex.org/keywords/medicine |
| keywords[6].score | 0.5258634090423584 |
| keywords[6].display_name | Medicine |
| keywords[7].id | https://openalex.org/keywords/immunology |
| keywords[7].score | 0.5093683004379272 |
| keywords[7].display_name | Immunology |
| keywords[8].id | https://openalex.org/keywords/cd8 |
| keywords[8].score | 0.49615010619163513 |
| keywords[8].display_name | CD8 |
| keywords[9].id | https://openalex.org/keywords/cancer |
| keywords[9].score | 0.49069130420684814 |
| keywords[9].display_name | Cancer |
| keywords[10].id | https://openalex.org/keywords/cpg-site |
| keywords[10].score | 0.48008233308792114 |
| keywords[10].display_name | CpG site |
| keywords[11].id | https://openalex.org/keywords/acquired-immune-system |
| keywords[11].score | 0.4313780963420868 |
| keywords[11].display_name | Acquired immune system |
| keywords[12].id | https://openalex.org/keywords/innate-immune-system |
| keywords[12].score | 0.42461562156677246 |
| keywords[12].display_name | Innate immune system |
| keywords[13].id | https://openalex.org/keywords/immune-checkpoint |
| keywords[13].score | 0.4163641333580017 |
| keywords[13].display_name | Immune checkpoint |
| keywords[14].id | https://openalex.org/keywords/antibody |
| keywords[14].score | 0.3871949017047882 |
| keywords[14].display_name | Antibody |
| keywords[15].id | https://openalex.org/keywords/biology |
| keywords[15].score | 0.28587204217910767 |
| keywords[15].display_name | Biology |
| keywords[16].id | https://openalex.org/keywords/internal-medicine |
| keywords[16].score | 0.128734290599823 |
| keywords[16].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.1158/0008-5472.can-16-1873 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S168522863 |
| locations[0].source.issn | 0008-5472, 1538-7445 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0008-5472 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Cancer Research |
| locations[0].source.host_organization | https://openalex.org/P4310320273 |
| locations[0].source.host_organization_name | American Association for Cancer Research |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320273 |
| locations[0].license | |
| locations[0].pdf_url | https://cancerres.aacrjournals.org/content/canres/77/2/312.full.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Cancer Research |
| locations[0].landing_page_url | https://doi.org/10.1158/0008-5472.can-16-1873 |
| locations[1].id | pmid:27872096 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Cancer research |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/27872096 |
| locations[2].id | pmh:oai:dipot.ulb.ac.be:2013/250584 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401063 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) |
| locations[2].source.host_organization | https://openalex.org/I132053463 |
| locations[2].source.host_organization_name | Université Libre de Bruxelles |
| locations[2].source.host_organization_lineage | https://openalex.org/I132053463 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | info:eu-repo/semantics/article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Cancer research, 77 (2 |
| locations[2].landing_page_url | http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/250584 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5049869535 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Roxanne Charlebois |
| authorships[0].countries | CA |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210142730 |
| authorships[0].affiliations[0].raw_affiliation_string | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada. |
| authorships[0].affiliations[1].raw_affiliation_string | 2Institut du Cancer de Montréal, Montréal, Québec, Canada. |
| authorships[0].institutions[0].id | https://openalex.org/I4210142730 |
| authorships[0].institutions[0].ror | https://ror.org/0410a8y51 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210142730 |
| authorships[0].institutions[0].country_code | CA |
| authorships[0].institutions[0].display_name | Centre Hospitalier de l’Université de Montréal |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Roxanne Charlebois |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada., 2Institut du Cancer de Montréal, Montréal, Québec, Canada. |
| authorships[1].author.id | https://openalex.org/A5073563331 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-2513-5978 |
| authorships[1].author.display_name | Bertrand Allard |
| authorships[1].countries | CA |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210142730 |
| authorships[1].affiliations[0].raw_affiliation_string | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada. |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I70931966 |
| authorships[1].affiliations[1].raw_affiliation_string | 3Faculté de Pharmacie, Université de Montréal, Québec, Canada. |
| authorships[1].affiliations[2].raw_affiliation_string | 2Institut du Cancer de Montréal, Montréal, Québec, Canada. |
| authorships[1].institutions[0].id | https://openalex.org/I4210142730 |
| authorships[1].institutions[0].ror | https://ror.org/0410a8y51 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210142730 |
| authorships[1].institutions[0].country_code | CA |
| authorships[1].institutions[0].display_name | Centre Hospitalier de l’Université de Montréal |
| authorships[1].institutions[1].id | https://openalex.org/I70931966 |
| authorships[1].institutions[1].ror | https://ror.org/0161xgx34 |
| authorships[1].institutions[1].type | education |
| authorships[1].institutions[1].lineage | https://openalex.org/I70931966 |
| authorships[1].institutions[1].country_code | CA |
| authorships[1].institutions[1].display_name | Université de Montréal |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Bertrand Allard |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada., 2Institut du Cancer de Montréal, Montréal, Québec, Canada., 3Faculté de Pharmacie, Université de Montréal, Québec, Canada. |
| authorships[2].author.id | https://openalex.org/A5041459747 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-8820-8161 |
| authorships[2].author.display_name | David Allard |
| authorships[2].countries | CA |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210142730 |
| authorships[2].affiliations[0].raw_affiliation_string | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada. |
| authorships[2].affiliations[1].raw_affiliation_string | 2Institut du Cancer de Montréal, Montréal, Québec, Canada. |
| authorships[2].affiliations[2].institution_ids | https://openalex.org/I70931966 |
| authorships[2].affiliations[2].raw_affiliation_string | 3Faculté de Pharmacie, Université de Montréal, Québec, Canada. |
| authorships[2].institutions[0].id | https://openalex.org/I4210142730 |
| authorships[2].institutions[0].ror | https://ror.org/0410a8y51 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210142730 |
| authorships[2].institutions[0].country_code | CA |
| authorships[2].institutions[0].display_name | Centre Hospitalier de l’Université de Montréal |
| authorships[2].institutions[1].id | https://openalex.org/I70931966 |
| authorships[2].institutions[1].ror | https://ror.org/0161xgx34 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I70931966 |
| authorships[2].institutions[1].country_code | CA |
| authorships[2].institutions[1].display_name | Université de Montréal |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | David Allard |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada., 2Institut du Cancer de Montréal, Montréal, Québec, Canada., 3Faculté de Pharmacie, Université de Montréal, Québec, Canada. |
| authorships[3].author.id | https://openalex.org/A5034407564 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-3751-0819 |
| authorships[3].author.display_name | Laurence Buisseret |
| authorships[3].countries | BE, CA |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I132053463, https://openalex.org/I2801838318 |
| authorships[3].affiliations[0].raw_affiliation_string | 5Breast Cancer Translational Research Laboratory J-C Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[3].affiliations[1].institution_ids | https://openalex.org/I4210142730 |
| authorships[3].affiliations[1].raw_affiliation_string | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada. |
| authorships[3].affiliations[2].raw_affiliation_string | 2Institut du Cancer de Montréal, Montréal, Québec, Canada. |
| authorships[3].affiliations[3].institution_ids | https://openalex.org/I132053463, https://openalex.org/I2801838318 |
| authorships[3].affiliations[3].raw_affiliation_string | 4Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[3].affiliations[4].institution_ids | https://openalex.org/I70931966 |
| authorships[3].affiliations[4].raw_affiliation_string | 3Faculté de Pharmacie, Université de Montréal, Québec, Canada. |
| authorships[3].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[3].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[3].institutions[0].country_code | BE |
| authorships[3].institutions[0].display_name | Institut Jules Bordet |
| authorships[3].institutions[1].id | https://openalex.org/I132053463 |
| authorships[3].institutions[1].ror | https://ror.org/01r9htc13 |
| authorships[3].institutions[1].type | education |
| authorships[3].institutions[1].lineage | https://openalex.org/I132053463 |
| authorships[3].institutions[1].country_code | BE |
| authorships[3].institutions[1].display_name | Université Libre de Bruxelles |
| authorships[3].institutions[2].id | https://openalex.org/I4210142730 |
| authorships[3].institutions[2].ror | https://ror.org/0410a8y51 |
| authorships[3].institutions[2].type | healthcare |
| authorships[3].institutions[2].lineage | https://openalex.org/I4210142730 |
| authorships[3].institutions[2].country_code | CA |
| authorships[3].institutions[2].display_name | Centre Hospitalier de l’Université de Montréal |
| authorships[3].institutions[3].id | https://openalex.org/I70931966 |
| authorships[3].institutions[3].ror | https://ror.org/0161xgx34 |
| authorships[3].institutions[3].type | education |
| authorships[3].institutions[3].lineage | https://openalex.org/I70931966 |
| authorships[3].institutions[3].country_code | CA |
| authorships[3].institutions[3].display_name | Université de Montréal |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Laurence Buisseret |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada., 2Institut du Cancer de Montréal, Montréal, Québec, Canada., 3Faculté de Pharmacie, Université de Montréal, Québec, Canada., 4Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., 5Breast Cancer Translational Research Laboratory J-C Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[4].author.id | https://openalex.org/A5012901674 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Martin Turcotte |
| authorships[4].countries | CA |
| authorships[4].affiliations[0].raw_affiliation_string | 2Institut du Cancer de Montréal, Montréal, Québec, Canada. |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I4210142730 |
| authorships[4].affiliations[1].raw_affiliation_string | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada. |
| authorships[4].affiliations[2].institution_ids | https://openalex.org/I70931966 |
| authorships[4].affiliations[2].raw_affiliation_string | 3Faculté de Pharmacie, Université de Montréal, Québec, Canada. |
| authorships[4].institutions[0].id | https://openalex.org/I4210142730 |
| authorships[4].institutions[0].ror | https://ror.org/0410a8y51 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210142730 |
| authorships[4].institutions[0].country_code | CA |
| authorships[4].institutions[0].display_name | Centre Hospitalier de l’Université de Montréal |
| authorships[4].institutions[1].id | https://openalex.org/I70931966 |
| authorships[4].institutions[1].ror | https://ror.org/0161xgx34 |
| authorships[4].institutions[1].type | education |
| authorships[4].institutions[1].lineage | https://openalex.org/I70931966 |
| authorships[4].institutions[1].country_code | CA |
| authorships[4].institutions[1].display_name | Université de Montréal |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Martin Turcotte |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada., 2Institut du Cancer de Montréal, Montréal, Québec, Canada., 3Faculté de Pharmacie, Université de Montréal, Québec, Canada. |
| authorships[5].author.id | https://openalex.org/A5021556566 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-4701-7112 |
| authorships[5].author.display_name | Sandra Pommey |
| authorships[5].countries | CA |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210142730 |
| authorships[5].affiliations[0].raw_affiliation_string | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada. |
| authorships[5].affiliations[1].institution_ids | https://openalex.org/I70931966 |
| authorships[5].affiliations[1].raw_affiliation_string | 3Faculté de Pharmacie, Université de Montréal, Québec, Canada. |
| authorships[5].affiliations[2].raw_affiliation_string | 2Institut du Cancer de Montréal, Montréal, Québec, Canada. |
| authorships[5].institutions[0].id | https://openalex.org/I4210142730 |
| authorships[5].institutions[0].ror | https://ror.org/0410a8y51 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210142730 |
| authorships[5].institutions[0].country_code | CA |
| authorships[5].institutions[0].display_name | Centre Hospitalier de l’Université de Montréal |
| authorships[5].institutions[1].id | https://openalex.org/I70931966 |
| authorships[5].institutions[1].ror | https://ror.org/0161xgx34 |
| authorships[5].institutions[1].type | education |
| authorships[5].institutions[1].lineage | https://openalex.org/I70931966 |
| authorships[5].institutions[1].country_code | CA |
| authorships[5].institutions[1].display_name | Université de Montréal |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Sandra Pommey |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada., 2Institut du Cancer de Montréal, Montréal, Québec, Canada., 3Faculté de Pharmacie, Université de Montréal, Québec, Canada. |
| authorships[6].author.id | https://openalex.org/A5056764614 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-3376-953X |
| authorships[6].author.display_name | Pavel Chrobák |
| authorships[6].countries | CA |
| authorships[6].affiliations[0].raw_affiliation_string | 2Institut du Cancer de Montréal, Montréal, Québec, Canada. |
| authorships[6].affiliations[1].institution_ids | https://openalex.org/I70931966 |
| authorships[6].affiliations[1].raw_affiliation_string | 3Faculté de Pharmacie, Université de Montréal, Québec, Canada. |
| authorships[6].affiliations[2].institution_ids | https://openalex.org/I4210142730 |
| authorships[6].affiliations[2].raw_affiliation_string | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada. |
| authorships[6].institutions[0].id | https://openalex.org/I4210142730 |
| authorships[6].institutions[0].ror | https://ror.org/0410a8y51 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210142730 |
| authorships[6].institutions[0].country_code | CA |
| authorships[6].institutions[0].display_name | Centre Hospitalier de l’Université de Montréal |
| authorships[6].institutions[1].id | https://openalex.org/I70931966 |
| authorships[6].institutions[1].ror | https://ror.org/0161xgx34 |
| authorships[6].institutions[1].type | education |
| authorships[6].institutions[1].lineage | https://openalex.org/I70931966 |
| authorships[6].institutions[1].country_code | CA |
| authorships[6].institutions[1].display_name | Université de Montréal |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Pavel Chrobak |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada., 2Institut du Cancer de Montréal, Montréal, Québec, Canada., 3Faculté de Pharmacie, Université de Montréal, Québec, Canada. |
| authorships[7].author.id | https://openalex.org/A5047414830 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-7833-4228 |
| authorships[7].author.display_name | John Stagg |
| authorships[7].countries | CA |
| authorships[7].affiliations[0].raw_affiliation_string | 2Institut du Cancer de Montréal, Montréal, Québec, Canada. |
| authorships[7].affiliations[1].institution_ids | https://openalex.org/I70931966 |
| authorships[7].affiliations[1].raw_affiliation_string | 3Faculté de Pharmacie, Université de Montréal, Québec, Canada. |
| authorships[7].affiliations[2].institution_ids | https://openalex.org/I4210142730 |
| authorships[7].affiliations[2].raw_affiliation_string | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada. |
| authorships[7].institutions[0].id | https://openalex.org/I4210142730 |
| authorships[7].institutions[0].ror | https://ror.org/0410a8y51 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210142730 |
| authorships[7].institutions[0].country_code | CA |
| authorships[7].institutions[0].display_name | Centre Hospitalier de l’Université de Montréal |
| authorships[7].institutions[1].id | https://openalex.org/I70931966 |
| authorships[7].institutions[1].ror | https://ror.org/0161xgx34 |
| authorships[7].institutions[1].type | education |
| authorships[7].institutions[1].lineage | https://openalex.org/I70931966 |
| authorships[7].institutions[1].country_code | CA |
| authorships[7].institutions[1].display_name | Université de Montréal |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | John Stagg |
| authorships[7].is_corresponding | True |
| authorships[7].raw_affiliation_strings | 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada., 2Institut du Cancer de Montréal, Montréal, Québec, Canada., 3Faculté de Pharmacie, Université de Montréal, Québec, Canada. |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://cancerres.aacrjournals.org/content/canres/77/2/312.full.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-23T05:10:03.516525 |
| primary_topic.id | https://openalex.org/T10158 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Immunotherapy and Biomarkers |
| related_works | https://openalex.org/W1551592253, https://openalex.org/W2050558417, https://openalex.org/W4225914417, https://openalex.org/W2135436588, https://openalex.org/W3030144597, https://openalex.org/W2498374562, https://openalex.org/W2951371476, https://openalex.org/W2044757050, https://openalex.org/W4231524083, https://openalex.org/W2073938056 |
| cited_by_count | 31 |
| counts_by_year[0].year | 2024 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2022 |
| counts_by_year[1].cited_by_count | 6 |
| counts_by_year[2].year | 2021 |
| counts_by_year[2].cited_by_count | 2 |
| counts_by_year[3].year | 2020 |
| counts_by_year[3].cited_by_count | 8 |
| counts_by_year[4].year | 2019 |
| counts_by_year[4].cited_by_count | 2 |
| counts_by_year[5].year | 2018 |
| counts_by_year[5].cited_by_count | 4 |
| counts_by_year[6].year | 2017 |
| counts_by_year[6].cited_by_count | 8 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1158/0008-5472.can-16-1873 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S168522863 |
| best_oa_location.source.issn | 0008-5472, 1538-7445 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0008-5472 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Cancer Research |
| best_oa_location.source.host_organization | https://openalex.org/P4310320273 |
| best_oa_location.source.host_organization_name | American Association for Cancer Research |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320273 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://cancerres.aacrjournals.org/content/canres/77/2/312.full.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Cancer Research |
| best_oa_location.landing_page_url | https://doi.org/10.1158/0008-5472.can-16-1873 |
| primary_location.id | doi:10.1158/0008-5472.can-16-1873 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S168522863 |
| primary_location.source.issn | 0008-5472, 1538-7445 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0008-5472 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Cancer Research |
| primary_location.source.host_organization | https://openalex.org/P4310320273 |
| primary_location.source.host_organization_name | American Association for Cancer Research |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320273 |
| primary_location.license | |
| primary_location.pdf_url | https://cancerres.aacrjournals.org/content/canres/77/2/312.full.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Cancer Research |
| primary_location.landing_page_url | https://doi.org/10.1158/0008-5472.can-16-1873 |
| publication_date | 2016-11-21 |
| publication_year | 2016 |
| referenced_works | https://openalex.org/W2137228442, https://openalex.org/W2129749518, https://openalex.org/W2221588520, https://openalex.org/W2112434826, https://openalex.org/W2290107239, https://openalex.org/W2260659963, https://openalex.org/W2407664560, https://openalex.org/W2066471812, https://openalex.org/W2152811375, https://openalex.org/W1525138842, https://openalex.org/W2051122657, https://openalex.org/W1973550352, https://openalex.org/W2173303337, https://openalex.org/W2109347785, https://openalex.org/W2147346150, https://openalex.org/W2142294973, https://openalex.org/W2177555958, https://openalex.org/W2127276356, https://openalex.org/W2049553585, https://openalex.org/W2152061559, https://openalex.org/W2114666853, https://openalex.org/W2088139924, https://openalex.org/W2147598914, https://openalex.org/W2083022271, https://openalex.org/W2125885282, https://openalex.org/W2291298003, https://openalex.org/W2096461956, https://openalex.org/W2081796577, https://openalex.org/W2213473402 |
| referenced_works_count | 29 |
| abstract_inverted_index.I | 43, 149 |
| abstract_inverted_index.T | 104, 161 |
| abstract_inverted_index.a | 38, 92, 132, 144 |
| abstract_inverted_index.II | 45, 151 |
| abstract_inverted_index.In | 20 |
| abstract_inverted_index.We | 76 |
| abstract_inverted_index.an | 7 |
| abstract_inverted_index.as | 18, 153, 155 |
| abstract_inverted_index.in | 10, 68, 79, 96, 118, 131, 184 |
| abstract_inverted_index.of | 14, 53, 60, 72, 82, 127, 139, 169 |
| abstract_inverted_index.to | 33, 49, 87, 100, 114, 121, 165 |
| abstract_inverted_index.we | 56 |
| abstract_inverted_index.CpG | 64, 85, 111, 128, 178 |
| abstract_inverted_index.RNA | 175 |
| abstract_inverted_index.and | 2, 35, 44, 63, 84, 110, 129, 150, 159, 177 |
| abstract_inverted_index.are | 30, 47 |
| abstract_inverted_index.mAb | 90, 123, 142 |
| abstract_inverted_index.our | 187 |
| abstract_inverted_index.the | 11, 21, 50, 58, 137, 166, 170 |
| abstract_inverted_index.was | 112 |
| abstract_inverted_index.CD8+ | 103, 160 |
| abstract_inverted_index.IFNs | 46 |
| abstract_inverted_index.Res; | 196 |
| abstract_inverted_index.Type | 148 |
| abstract_inverted_index.able | 99 |
| abstract_inverted_index.been | 181 |
| abstract_inverted_index.have | 37, 180 |
| abstract_inverted_index.mAb, | 55 |
| abstract_inverted_index.more | 31 |
| abstract_inverted_index.play | 6 |
| abstract_inverted_index.role | 9 |
| abstract_inverted_index.situ | 80 |
| abstract_inverted_index.such | 17 |
| abstract_inverted_index.that | 78 |
| abstract_inverted_index.type | 42 |
| abstract_inverted_index.used | 183 |
| abstract_inverted_index.well | 154 |
| abstract_inverted_index.were | 163 |
| abstract_inverted_index.with | 27, 65, 192 |
| abstract_inverted_index.AACR. | 200 |
| abstract_inverted_index.IFNs, | 152 |
| abstract_inverted_index.Local | 125 |
| abstract_inverted_index.cells | 5, 29, 158 |
| abstract_inverted_index.mAbs, | 16 |
| abstract_inverted_index.mAbs. | 194 |
| abstract_inverted_index.mouse | 70 |
| abstract_inverted_index.study | 188 |
| abstract_inverted_index.tumor | 134 |
| abstract_inverted_index.worse | 39 |
| abstract_inverted_index.77(2); | 197 |
| abstract_inverted_index.Cancer | 195 |
| abstract_inverted_index.ErbB2+ | 73 |
| abstract_inverted_index.Innate | 1 |
| abstract_inverted_index.breast | 23, 74, 97 |
| abstract_inverted_index.cells, | 162 |
| abstract_inverted_index.effect | 59 |
| abstract_inverted_index.immune | 4, 28 |
| abstract_inverted_index.induce | 101 |
| abstract_inverted_index.killer | 157 |
| abstract_inverted_index.models | 71 |
| abstract_inverted_index.poorly | 25 |
| abstract_inverted_index.potent | 93 |
| abstract_inverted_index.safely | 182 |
| abstract_inverted_index.tumor. | 147 |
| abstract_inverted_index.tumors | 24, 98, 120 |
| abstract_inverted_index.©2016 | 199 |
| abstract_inverted_index.Because | 41, 173 |
| abstract_inverted_index.against | 143 |
| abstract_inverted_index.cancer. | 75 |
| abstract_inverted_index.clinic, | 22 |
| abstract_inverted_index.distant | 145 |
| abstract_inverted_index.natural | 156 |
| abstract_inverted_index.polyI:C | 62, 83, 109, 130 |
| abstract_inverted_index.primary | 133 |
| abstract_inverted_index.therapy | 67 |
| abstract_inverted_index.trials, | 186 |
| abstract_inverted_index.312–9. | 198 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.activity | 13, 52, 138, 168 |
| abstract_inverted_index.adaptive | 3 |
| abstract_inverted_index.blockade | 117 |
| abstract_inverted_index.clinical | 185 |
| abstract_inverted_index.combined | 86, 115 |
| abstract_inverted_index.critical | 48 |
| abstract_inverted_index.delivery | 81 |
| abstract_inverted_index.enhanced | 136 |
| abstract_inverted_index.patients | 36 |
| abstract_inverted_index.response | 95 |
| abstract_inverted_index.superior | 113 |
| abstract_inverted_index.supports | 189 |
| abstract_inverted_index.systemic | 88, 140 |
| abstract_inverted_index.therapy. | 124 |
| abstract_inverted_index.analogues | 176 |
| abstract_inverted_index.antitumor | 106 |
| abstract_inverted_index.combining | 61 |
| abstract_inverted_index.immunity. | 107 |
| abstract_inverted_index.important | 8 |
| abstract_inverted_index.injection | 126 |
| abstract_inverted_index.resistant | 32 |
| abstract_inverted_index.synthetic | 174 |
| abstract_inverted_index.triggered | 91 |
| abstract_inverted_index.untreated | 146 |
| abstract_inverted_index.anti-ErbB2 | 15, 54, 89, 122, 141, 193 |
| abstract_inverted_index.prognosis. | 40 |
| abstract_inverted_index.treatment. | 172 |
| abstract_inverted_index.treatments | 191 |
| abstract_inverted_index.PD-1/CTLA-4 | 116 |
| abstract_inverted_index.Remarkably, | 108 |
| abstract_inverted_index.combination | 171, 190 |
| abstract_inverted_index.infiltrated | 26 |
| abstract_inverted_index.sensitizing | 119 |
| abstract_inverted_index.synergistic | 167 |
| abstract_inverted_index.therapeutic | 12 |
| abstract_inverted_index.demonstrated | 77 |
| abstract_inverted_index.inflammatory | 94 |
| abstract_inverted_index.investigated | 57 |
| abstract_inverted_index.long-lasting | 102 |
| abstract_inverted_index.trastuzumab, | 34 |
| abstract_inverted_index.trastuzumab. | 19 |
| abstract_inverted_index.indispensible | 164 |
| abstract_inverted_index.significantly | 135 |
| abstract_inverted_index.immune-mediated | 51 |
| abstract_inverted_index.immunocompetent | 69 |
| abstract_inverted_index.cell–dependent | 105 |
| abstract_inverted_index.trastuzumab-like | 66 |
| abstract_inverted_index.oligodeoxynucleotides | 179 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 90 |
| corresponding_author_ids | https://openalex.org/A5047414830 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 8 |
| corresponding_institution_ids | https://openalex.org/I4210142730, https://openalex.org/I70931966 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8500000238418579 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.89892989 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |